Jiwei He

Jiwei He

Auto-generated profile, based on publicly available information

Jiwei He

Division of Biometrics VII, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2014 in Cancer
Verified
Journal Article
Closed access
PDF file
JCJohn P. Christodouleas
John P. Christodouleas
BBBrian C. Baumann
Brian C. Baumann
JHJiwei He
Jiwei He
WHWei-Ting Hwang
Wei-Ting Hwang
KTKai N. Tucker
Kai N. Tucker
SMS. Bruce Malkowicz
S. Bruce Malkowicz

27 March 2023 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
YWYun Wang
Yun Wang
WTWenda Tu
Wenda Tu
YKYoonhee Kim
Yoonhee Kim
SSSusie Sinks
Susie Sinks
JHJiwei He
Jiwei He
JCJennifer Clark
Jennifer Clark

11 March 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
SWShirley V. Wang
Shirley V. Wang
MRMassimiliano Russo
Massimiliano Russo
RGRobert J. Glynn
Robert J. Glynn
MBMarie C. Bradley
Marie C. Bradley
JHJiwei He
Jiwei He
SSSebastian Schneeweiss
Sebastian Schneeweiss
Real‐world evidence involving healthcare database studies is well established for making causal inferences in post‐market drug safety studies and methods, data, and research infrastructure for evaluating effectiveness have advanced in recent years. The rapidly expanding field of etiologic research using insurance claims and electronic health records databases is being evaluated for supporting effectiveness claims. One such use case to support regulatory decision‐making on effectiveness is for expanding indications beyond existing effectiveness claims. Confidence in the validity of findings from cohort studies conducted using databases (hereafter “database study”) to support indication expansions could be increased through a structured benchmarking process of an initial database study against RCT evidence followed by calibration of a subsequent database study based on differences in results observed in the initial RCT‐database pair. This paper proposes a benchmark, expand, and calibration (BenchExCal) approach to trial emulation and describes the design and process for evaluating the performance of the approach through both simulation studies; five planned empirical examples are also described. The project will provide insights regarding how a first‐stage benchmarking emulation of a completed trial for an existing indication can be used to calibrate, increase confidence, and improve interpretation of the results for a second‐stage emulation of a hypothetical trial that could potentially provide evidence for an expanded indication. Although the examples have been selected to provide a variety of learnings, five use cases do not address all clinical and data scenarios that may be encountered when seeking a supplemental indication for a marketed drug.

5 October 2017 in Statistical Methods in Medical Research
Verified
Journal Article
Closed access
JHJiwei He
Jiwei He
ASAlisa Stephens-Shields
Alisa Stephens-Shields
MJMarshall Joffe
Marshall Joffe
Marginal structural models are a class of causal models useful for characterizing the effect of treatment in the presence of time-varying confounding. They are more widely used than structural nested models, partly because these models are easier to understand and to implement. We extend marginal structural models to situations with clustered observations with unit- and cluster-level treatment and introduce an appropriate inferential method. We consider how to formulate models with cluster-level and unit-level treatments. For unit-level treatments, we consider cases with and without interference. We also consider the use of unit-specific inverse probability weights and certain working correlation structures to improve the efficiency of estimators in some situations. We apply our method to different scenarios including 2 or 3 units per cluster and a mixture of larger clusters. Simulation examples and data from the treatment arm of a glaucoma clinical trial were used to illustrate our method.

19 September 2022 in Journal of Biopharmaceutical Statistics
Verified
Journal Article
Closed access
JHJiwei He
Jiwei He
RCRoberto Crackel
Roberto Crackel
WKWilliam Koh
William Koh
LCLing-Wan Chen
Ling-Wan Chen
FLFeng Li
Feng Li
MRMark Rothmann
Mark Rothmann
Recently, retrieved-dropout-based multiple imputation has been used in some therapeutic areas to address the treatment policy estimand, mostly for continuous endpoints. In this approach, data from subjects who discontinued study treatment but remained in study were used to construct a model for multiple imputation for the missing data of subjects in the same treatment arm who discontinued study. We extend this approach to time-to-event endpoints and provide a practical guide for its implementation. We use a cardiovascular outcome trial dataset to illustrate the method and compare the results with those from Cox proportional hazard and reference-based multiple imputation methods.

21 October 2020 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
PSPamela A. Shaw
Pamela A. Shaw
JHJiwei He
Jiwei He
BSBryan E. Shepherd
Bryan E. Shepherd